B. Multivariable logistic regression analysis for IFX absence at W54 including ITL at W2 (Model I) and at W6 (Model II) as possible predictors.
Factors |
OR |
95%CI |
Model I |
|
|
Female sex |
1.09 |
0.09-13.18 |
Age |
1.09 |
1.03-1.17 |
DAS28 |
0.64 |
0.36-1.14 |
MTX non-use |
12.26 |
1.83-82.22 |
Levels below cut-off at W2 (21.2 μg/mL) |
15.85 |
2.95-85.03 |
Model II |
|
|
Female sex |
0.65 |
0.05-7.97 |
Age |
1.05 |
0.98-1.12 |
DAS28 |
0.64 |
0.31-1.30 |
MTX non-use |
6.91 |
1.04-45.84 |
Levels below cut-off at W6 (4.4 μg/mL) |
86.64 |
6.58-1139.99 |
ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; CI, confidence interval; DAS28, Disease Activity Score in 28 joints; MTX, methotrexate; OR, odds ratio; TNF-α, tumour necrosis factor α; ITL, Infliximab trough levels.